Fluxion, Stanford School of Medicine team up
SOUTH SAN FRANCISCO, Calif.—A recently established collaborative effort between Fluxion Biosciences Inc. and the Stanford University School of Medicine is seeking to develop tests that will help lead to more effective therapies for cancer patients. Dr. Stefanie Jeffrey's laboratory will use Fluxion's IsoFlux System to locate and analyze circulating cancer cells, which break off from primary tumors to enter the bloodstream and are known to contribute to cancer metastasis in carcinomas such as breast, prostate, colorectal, lung and pancreatic cancer. The IsoFlux System uses proprietary microfluidic technology to isolate rare cells, resulting in high-quality samples ready for downstream analysis. The partners will be focusing on breast and lung cancer pathologies, seeking to subtype different forms of the disease in order to develop more effective and patient-specific treatments.